ArticleACS omega2020
Homology Modeling of Leishmanolysin (gp63) from
Article in ACS omega, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Antileishmanial Activity of Bioactive Compounds Obtained fromMolecules (Basel, Switzerland) · 2026Pooled it
- Article
- Article
- Silver-Pharmaceuticals (Basel, Switzerland) · 2026Article
- Parasite in cancer therapy: molecular mechanisms and translational potential.Frontiers in immunology · 2026Review
- Molecular docking and simulation analysis of selected herbal compounds against GP63, FPPS, and NMT, three importantResearch in pharmaceutical sciences · 2025Article
- Advances in the study of extracellular vesicles of Naegleria fowleri and their role in contact-independent pathogenic mechanisms.Parasites & vectors · 2025Article
- Investigating the potent TOPO IIα inhibitors in breast cancer through the study of computational drug discovery research approaches.Molecular diversity · 2025Article
- Advances and Challenges in Molecular Docking Applied to Neglected Tropical Diseases.Current medicinal chemistry · 2025Review
- Healing and leishmanicidal activity ofFrontiers in chemistry · 2025Article
- Exploration of the Binding Site of Arachidonic Acid in gp63 ofPathogens (Basel, Switzerland) · 2024Article
- Genomic Insight of Leishmania Parasite: In-Depth Review of Drug Resistance Mechanisms and Genetic Mutations.ACS omega · 2024Review
- Antileishmanial Activity and In Silico Molecular Docking Studies ofTropical medicine and infectious disease · 2023Article
- Bioinformatics evaluation of anticancer properties of GP63 protein-derived peptides on MMP2 protein of melanoma cancer.Journal of pathology informatics · 2023Article
- Screening of medicinal plants unraveled the leishmanicidal credibility ofJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2022Article
- Review
- Hinokiflavone and Related C-O-C-Type Biflavonoids as Anti-cancer Compounds: Properties and Mechanism of Action.Natural products and bioprospecting · 2021Review
- Analysis of Kojic Acid Derivatives as Competitive Inhibitors of Tyrosinase: A Molecular Modeling Approach.Molecules (Basel, Switzerland) · 2021Article
- Natural Products That Target the Arginase inMicroorganisms · 2021Review
- Use of Natural Products in Leishmaniasis Chemotherapy: An Overview.Frontiers in chemistry · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leishmaniasis is a chronic disease caused by protozoa of the distinct
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.